Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(13 sites)

Austria

Medical University of Graz, Graz

France

Hospital Beaujon, Clichy

Germany

University Hospital of Dusseldorf, Düsseldorf

Goethe University Frankfurt, Frankfurt

Medizinische Hochschule Hannover, Hanover

Romania

Centrul Medical Unirea S.R.L, Iași, Lasi

Clinical Hospital for Infectious and Tropical Diseases Dr. Victor Babes, Bucharest

National Institute Of Infectious Diseases Prof. Dr. Matei Bals, Bucharest

Spitalul Clinic de Boli Infectioase Constanta, Constanța

United Kingdom

Castle Hill Hospital, Cottingham, Yorkshire

Barts Health NHS Trust, London

King's College Hospital NHS Foundation Trust, London

Chelsea and Westminster Hospital, London